Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study

Nathalie Rochet, Meinhard Kieser, Florian Sterzing, Sonja Krause, Katja Lindel, Wolfgang Harms, Michael H Eichbaum, Andreas Schneeweiss, Christof Sohn, Juergen Debus, Nathalie Rochet, Meinhard Kieser, Florian Sterzing, Sonja Krause, Katja Lindel, Wolfgang Harms, Michael H Eichbaum, Andreas Schneeweiss, Christof Sohn, Juergen Debus

Abstract

Background: The prognosis for patients with advanced FIGO stage III epithelial ovarian cancer remains poor despite the aggressive standard treatment, consisting of maximal cytoreductive surgery and platinum-based chemotherapy. The median time to recurrence is less than 2 years, with a 5-years survival rate of -20-25%. Recurrences of the disease occur mostly intraperitoneally.Ovarian cancer is a radiosensitive tumor, so that the use of whole abdominal radiotherapy (WAR) as a consolidation therapy would appear to be a logical strategy. WAR used to be the standard treatment after surgery before the chemotherapy era; however, it has been almost totally excluded from the treatment of ovarian cancer during the past decade because of its high toxicity. Modern intensity-modulated radiation therapy (IMRT) has the potential of sparing organs at risk like kidneys, liver, and bone marrow while still adequately covering the peritoneal cavity with a homogenous dose.Our previous phase I study showed for the first time the clinical feasibility of intensity-modulated WAR and pointed out promising results concerning treatment tolerance. The current phase-II study succeeds to the phase-I study to further evaluate the toxicity of this new treatment.

Methods/design: The OVAR-IMRT-02 study is a single-center one arm phase-II trial. Thirty seven patients with optimally debulked ovarian cancer stage FIGO III having a complete remission after chemotherapy will be treated with intensity-modulated WAR as a consolidation therapy.A total dose of 30 Gy in 20 fractions of 1.5 Gy will be applied to the entire peritoneal cavity including the liver surface and the pelvic and para-aortic node regions. Organ at risk are kidneys, liver (except the 1 cm-outer border), heart, vertebral bodies and pelvic bones.Primary endpoint is tolerability; secondary objectives are toxicity, quality of life, progression-free and overall survival.

Discussion: Intensity-modulated WAR provides a new promising option in the consolidation treatment of ovarian carcinoma in patients with a complete pathologic remission after adjuvant chemotherapy. Further consequent studies will be needed to enable firm conclusions regarding the value of consolidation radiotherapy within the multimodal treatment of advanced ovarian cancer.

Trial registration: Clinicaltrials.gov: NCT01180504.

References

    1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259. doi: 10.1200/JCO.20.5.1248.
    1. Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD. et al.Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003;21:129s–132s. doi: 10.1200/JCO.2003.04.003.
    1. Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004;14:772–778. doi: 10.1111/j.1048-891X.2004.014507.x.
    1. McGuire WP III. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol. 2003;21:133s–135s. doi: 10.1200/JCO.2003.01.066.
    1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA. et al.Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200. doi: 10.1200/JCO.2003.02.153.
    1. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW. et al.Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2004;33:1219–1224. doi: 10.1038/sj.bmt.1704473.
    1. Dufour P, Bergerat JP, Barats JC, Giron C, Duclos B, Dellenbach P. et al.Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer. 1994;73:1865–1869. doi: 10.1002/1097-0142(19940401)73:7<1865::AID-CNCR2820730715>;2-T.
    1. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD. et al.Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:2849–2855. doi: 10.1200/JCO.2003.11.018.
    1. Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience. Cancer. 1985;55:2285–2290. doi: 10.1002/1097-0142(19850501)55:9+<2285::AID-CNCR2820551436>;2-4.
    1. Dembo AJ. Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys. 1992;22:835–845. doi: 10.1016/0360-3016(92)90777-F.
    1. Smith JP, Rutledge FN, Delclos L. Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. Natl Cancer Inst Monogr. 1975;42:149–153.
    1. Kapp KS, Kapp DS, Poschauko J, Stucklschweiger GF, Hackl A, Pickel H. et al.The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol. 1999;74:400–407. doi: 10.1006/gyno.1999.5477.
    1. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol. 1997;8:327–333. doi: 10.1023/A:1008256431090.
    1. MacGibbon A, Bucci J, MacLeod C, Solomon J, Dalrymple C, Firth I. et al.Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecol Oncol. 1999;75:62–67. doi: 10.1006/gyno.1999.5541.
    1. Pickel H, Lahousen M, Petru E, Stettner H, Hackl A, Kapp K. et al.Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol. 1999;72:215–219. doi: 10.1006/gyno.1998.5184.
    1. Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gynecol Oncol. 1993;51:97–103. doi: 10.1006/gyno.1993.1253.
    1. Thomas GM, Dembo AJ. Integrating radiation therapy into the management of ovarian cancer. Cancer. 1993;71:1710–1718. doi: 10.1002/1097-0142(19930315)71:6<1977::AID-CNCR2820710609>;2-D.
    1. Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer. 2003;13:278–286. doi: 10.1046/j.1525-1438.2003.13193.x.
    1. Einhorn N, Lundell M, Nilsson B, Ragnarsson-Olding B, Sjovall K. Is there place for radiotherapy in the treatment of advanced ovarian cancer? Radiother Oncol. 1999;53:213–218. doi: 10.1016/S0167-8140(99)00144-9.
    1. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol. 2003;42:562–566. doi: 10.1080/02841860310014426.
    1. Fyles AW, Thomas GM, Pintilie M, Ackerman I, Levin W. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II, and III ovarian cancer. Int J Radiat Oncol Biol Phys. 1998;41:543–549. doi: 10.1016/S0360-3016(98)00066-2.
    1. Dinniwell R, Lock M, Pintilie M, Fyles A, Laframboise S, Depetrillo D. et al.Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys. 2005;62:104–110. doi: 10.1016/j.ijrobp.2004.09.010.
    1. Whelan TJ, Dembo AJ, Bush RS, Sturgeon JF, Fine S, Pringle JF. et al.Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Radiat Oncol Biol Phys. 1992;22:853–858. doi: 10.1016/0360-3016(92)90779-H.
    1. Fuller DB, Sause WT, Plenk HP, Menlove RL. Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma. J Clin Oncol. 1987;5:897–905.
    1. Duthoy W, De Gersem W, Vergote K, Coghe M, Boterberg T, De Deene Y. et al.Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J Radiat Oncol Biol Phys. 2003;57:1019–1032. doi: 10.1016/S0360-3016(03)00663-1.
    1. Rochet N, Sterzing F, Jensen A, Dinkel J, Herfarth K, Schubert K. et al.Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Onkol. 2008;184:145–149. doi: 10.1007/s00066-008-1772-z.
    1. Debus J, Zierhut D, Didinger B, Schlegel W, Wannenmacher M. Inverse planning and intensity-modulated radiotherapy in patients with prostate cancer. Front Radiat Ther Oncol. 2002;36:25–34. full_text.
    1. Hong L, Alektiar K, Chui C, LoSasso T, Hunt M, Spirou S. et al.IMRT of large fields: whole-abdomen irradiation. Int J Radiat Oncol Biol Phys. 2002;54:278–289. doi: 10.1016/S0360-3016(02)03298-4.
    1. Mackie TR, Holmes T, Swerdloff S, Reckwerdt P, Deasy JO, Yang J. et al.Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys. 1993;20:1709–1719. doi: 10.1118/1.596958.
    1. Rochet N, Jensen AD, Sterzing F, Munter MW, Eichbaum MH, Schneeweiss A. et al.Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer. 2007;7:227. doi: 10.1186/1471-2407-7-227.
    1. Rochet N, Sterzing F, Jensen AD, Dinkel J, Herfarth KK, Schubert K. et al.Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys. 2010;76:1382–1389. doi: 10.1016/j.ijrobp.2009.03.061.
    1. Firat S, Murray K, Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys. 2003;57:201–207. doi: 10.1016/S0360-3016(03)00510-8.
    1. Fyles AW, Dembo AJ, Bush RS, Levin W, Manchul LA, Pringle JF. et al.Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys. 1992;22:847–851. doi: 10.1016/0360-3016(92)90778-G.
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10. doi: 10.1016/0197-2456(89)90015-9.
    1. Englert S, Kieser M. Adaptive designs for single-arm, phase II trials in oncology, Internal Report. 2010.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する